account for approximately 270,000 cases per year with underreporting estimated at approximately 20-fold 15 . Here we used a well-established model of murine peritonitis, relevant to human infections 16 , to identify specific SPMs that may be directly involved in resolving infections. E. coli inoculation at 10 5 c.f.u. per mouse intraperitoneally evoked a selflimited host response (Fig. 1a ). PMN infiltration reached maximum at approximately 12 h followed by decline. Monocyte/macrophage numbers gradually increased from 2 h to 72 h; most of the exudate mononuclear cells at later time points were macrophages (,90% CD14 1 F4/ 80 1 cells; Supplementary Fig. 1a ), a finding consistent with antiphlogistic actions of macrophages (for example, clearing apoptotic PMN) 6, 7 . To provide quantitative analysis of resolution components with E. coli infection, we used resolution indices 4 , because they give unbiased assessment of progress during resolution and are now in wide use (see refs 9, 17) . Resolution indices were time point when PMN numbers reach maximum (T max ) < 12 h and time point when PMN numbers reduce to 50% of maximum (T 50 ) < 28 h, giving a resolution interval (R i ) of 16 h (see Methods). In sharp contrast, inoculation at 10 7 c.f.u. per mouse delayed resolution with sustained PMN infiltration ( Fig. 1b ). PMN numbers continued to increase until 72 h and the major mononuclear cell type at later intervals was monocytes (,90% CD14 1 F4/80 2 ; Supplementary Fig. 1a ), with only approximately 6% macrophages. Also with the higher inoculum of 10 7 c.f.u., bacteria counts in both blood and lavages remained elevated at 24-48 h, whereas with lower E. coli inoculum bacteria were cleared by 24 h (Supplementary Fig. 1b ). Thus, high inoculum of 10 7 c.f.u. evoked excessive PMN accumulation and limited macrophages in exudates that reflect delayed resolution of infection. Importantly, the lower E. coli inoculum gave self-limited profiles (R i 5 16h), permitting differential analysis.
Infection-resolution metabololipidomics: Profiling metabololipidomics targeted on local acting lipid mediators (LM) was carried out with E. coli exudates using mass-spectrometry-based LM-lipidomics targeting five LM metabolomes, for example, leukotrienes, resolvins and protectins ( Fig. 1c and Supplementary Fig. 1 ). In self-resolving peritonitis (10 5 c.f.u.), biosynthetic pathway markers for protectin D1 (PD1) and maresins (MaR1), namely 17-HDHA and 14-HDHA, were identified and elevated at the peak of PMN infiltration approximately 12 h in resolving exudates (see Supplementary Table 1 for LM identification). By comparison, mice that received higher titre of E. coli (10 7 c.f.u.) gave increased levels of proinflammatory LTB 4 and reduced 17-HDHA and 14-HDHA levels at 12-48 h ( Fig. 1c and Supplementary  Fig. 1d ). Within the initial phase (4 h), RvD5 (7S,17S-dihydroxydocosa-4Z,8E,10Z,13Z,15E,19Z-hexaenoic acid), a pivotal biosynthetic marker 18 , accumulated in self-resolving exudates (120 6 39 pg per exudate), approximately three times more than in exudates from higher titre E. coli infections (40 6 11 pg RvD5 per exudate, P , 0.05) ( Fig. 1c and Supplementary Fig. 1 ). At later interval 12 h, RvD5 remained elevated (326 6 39 pg per exudate) in self-resolving exudates. It is noteworthy that PD1 levels were also significantly greater in self-resolving exudates (1,066 6 247 pg per exudate) than in higher titre E. coli-challenged mice (468 6 116 pg per exudate). In these exudates, RvD5 and PD1 were most abundant of the DHA metabolome. Human PMN transform 17-H(p)DHA via two distinct biosynthetic pathways to RvD5 and/or PD1 ( Supplementary Fig. 2) 4, 18 . These pathways were activated on infection and used endogenous essential fatty acids without supplement to biosynthesize potent novel mediators (see later). Their presence suggested specific role(s) in resolving infection.
RvD5 and PD1 both accumulated whereas RvD1 rapidly disappeared in exudates from E. coli infections. To monitor the metabolic flux of RvD1 during E. coli infections, RvD1 was administered with E. coli (10 5 c.f.u.) into the peritoneum ( Supplementary Fig. 3a ). At 12-24 h post-inoculation, only 5-10% RvD1 was recovered from peritoneal exudates. Along these lines, with human macrophages approximately 40-50% of RvD1 was lost within 0.5-2.0 h, accompanied by an increase in its further metabolite dihydro-RvD1. ( Supplementary Fig. 3b ). Hence, these are dynamic pathways in infectious exudates.
We calculated ratios for pro-resolving versus inflammatory mediators, that is, RvD5/LTB 4 and PD1/LTB 4 . In self-resolving exudates these ratios at 12 and 24 h were greater than those in exudates from higher (10 7 c.f.u.) E. coli infections ( Supplementary Fig. 1e ), indicating that differential LM exudate profiles were present with these E. coli infections. To access their potential endogenous roles, we profiled these pathways in germ-free mice 19 (Fig. 1d ). In colons of naive germ-free mice, lower amounts of LTB 4 were identified and increased levels of endogenous DHA products 14-HDHA, 17-HDHA, RvD1 and PD1 (Fig. 1e, f and Supplementary Fig. 4 ). Hence, both endogenous and infected tissues produced D-series resolvins and PD1.
Because D-series resolvins, in particular RvD5, were one of the more abundant SPMs, we sought to determine its impact in E. coli infections. RvD5 given in physiologic range, that is, nanograms per mouse with E. coli (10 7 c.f.u.) significantly enhanced phagocyte containment of E. coli in vivo (160% increase) compared to mice challenged with E. coli alone ( Fig. 2a ). RvD1 shared this action, registering 42% increase. Of note, RvD1 or RvD5 markedly reduced blood and exudate bacterial counts ( Fig. 2b ). Infected mice developed hypothermia, giving 2.4 6 1.2 uC decrements in body (surface) temperature. Both RvD1 and RvD5 prevented this ( Fig. 2c and Supplementary Fig. 5a ). The higher lethal dose of E. coli (2.5 3 10 7 c.f.u.) gave only 25% survival and RvD1 significantly increased survival to approximately 66% ( Fig. 2d and Supplementary Fig. 5b , P , 0.05). Here, RvD5 significantly reduced pro-inflammatory cytokines KC and TNF-a in exudates and RvD1 decreased IL-1b ( Supplementary Fig. 5c ). Thus, both RvD1 and RvD5 stimulated phagocyte E. coli ingestion, lowered bacterial titres, protected from hypothermia and increased survival. 
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Given these in vivo findings, we next questioned whether SPMs have a direct impact on bacterial containment with isolated human cells. RvD1, RvD5 and PD1 each potently enhanced human macrophage phagocytosis of fluorescent E. coli by approximately 40-70% increases in pM to nM ranges ( Fig. 3a-c ). We also tested whether RvD5 activates human RvD1 receptor GPR32 expressed in a beta-arrestin reporter system 20 , and found that RvD5 directly activates this receptor ( Supplementary Fig. 6a ). RvD5-enhanced phagocytic activity also proved dependent on GPR32. Both RvD1 and RvD5 increased macrophage phagocytosis of E. coli, an action further enhanced with GPR32 overexpression compared to mock-transfected cells ( Supplementary  Fig. 6b ).
Gene array analysis with human macrophages (.90 genes) showed that E. coli upregulated a panel of inflammation-related genes, including NF-kB, phosphodiesterase 4B (PDE4B), COX-2 (also known as PTGS2) and TNF-a (also known as TNF). These results are consistent with Gram-negative lipopolysaccharide (LPS) stimulation of macrophages that upregulates COX-2 (ref. 21) , PDE4B and TNF-a 22 . When RvD5 (1 nM) was incubated with macrophages and E. coli, many of these genes were downregulated. RvD1 downregulated, for example, PDE4B and COX-2 ( Fig. 3d and Supplementary Table 2 ). Ablation of PDE4B protects mice from LPS-induced septic shock 23 and inhibition of COX enhances bacterial clearance of penicillin-resistant Streptococcus pneumoniae 24 . Therefore, RvD1 and RvD5 each counter-regulate COX and proinflammatory signalling components initiated by E. coli that might contribute to their actions in enhancing non-phlogistic phagocytosis ( Fig. 3, Supplementary Table 2 ) and bacterial clearance in vivo (Fig. 2) .
Similar findings were obtained with human PMN, where RvD1, RvD5 and PD1 each stimulated PMN anti-microbial mechanisms, increasing E. coli ingestion and intracellular reactive oxygen species (ROS) production for killing during E. coli challenge ( Supplementary   Fig. 7) . These SPMs did not exhibit direct anti-bacterial activities ( Supplementary Fig. 8 ). Together, these results characterize antiphlogistic and host-directed antibacterial actions of RvD5, RvD1 and PD1 in that they enhance phagocytic activity of human phagocytes without evoking pro-inflammatory responses of these cells.
SPMs and antibiotics: Antibiotic-resistant bacteria are a global concern, increasing health-care costs. Ciprofloxacin, for example, is the only antibiotic recommended by the World Health Organization for management of bloody diarrhoea 25 . Unfortunately, rapid increases in bacterial resistance to ciprofloxacin reduces treatment options 25 . Hence, new strategies are needed. Given that specific SPMs enhanced bacterial containment (Figs 2, 3) , we questioned whether SPM-directed host responses would improve antibiotic treatment. To this end, we determined resolution indices for ciprofloxacin and RvD1. Given along with E. coli (10 5 c.f.u.), RvD1 (50 ng) reduced maximal PMN (Y max ), and shortened resolution interval (R i ) from approximately 20 h to approximately 12 h (Fig. 4a) . Ciprofloxacin alone at equi-doses also reduced R i to approximately 11 h and initiated resolution at an earlier point T max at about 6 h. RvD1 plus ciprofloxacin further accelerated the onset of resolution with T max < 4 h, and reduced R i to about 5 h ( Fig. 4a and Supplementary Table 3 ).
RvD1 plus ciprofloxacin further reduced bacterial titres in blood and exudates at 4 h, compared to ciprofloxacin alone (Fig. 4b) .
Similar results were obtained at 12 h with exudates, whereas there were no significant differences between ciprofloxacin and ciprofloxacin plus RvD1 in blood. RvD1 actions were more pronounced at 4 h in blood. A panel of cytokines/chemokines was monitored ( Supplementary Fig. 9a ), and RvD1 and ciprofloxacin each gave differential actions; RvD1 significantly reduced IL-1b, IL-6 and increased IL-10 at 4 h, and IFNc at 24 h. Ciprofloxacin alone reduced IL-12 levels at 4 h ( Supplementary  Fig. 9b ). We also assessed LM metabololipidomic profiles: RvD1 plus ciprofloxacin significantly increased both 14-HDHA and PD1 at 4 h ( Fig. 4c and Supplementary Fig. 9c, d) , whereas neither alone was effective. At 12 h, RvD1 or ciprofloxacin alone increased endogenous PD1. In addition, RvD1 or ciprofloxacin alone at 4 h did not enhance macrophage containment of E. coli, but significantly increased 
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phagocytic activity when both were administered ( Supplementary  Fig. 9e ). Thus, host-directed RvD1 responses plus bacteria-directed antibiotic accelerated resolution via enhanced E. coli killing and clearance, as well as selectively regulating both endogenous LM and cytokines. Because the specific SPMs identified in infectious exudates were from DHA metabolome ( Fig. 1) , we tested RvD1, RvD5 and PD1 together (50 ng each) plus ciprofloxacin (25 mg per mouse) in higher titre E. coli (10 7 c.f.u.) infections. Sub-optimal doses of ciprofloxacin (25 mg, Supplementary Fig. 10a ) still protected mice from hypothermia and reduced bacterial titres, actions that were enhanced by the SPM panel (Fig. 4d ). In addition, treatment with both ciprofloxacin and SPMs significantly increased phagocyte ingestion of E. coli, whereas neither treatment alone proved effective ( Supplementary Fig. 10b ).
SPMs enhance actions of vancomycin in S. aureus-initiated infections: Staphylococcus aureus is an emerging cause of various skin infections and a high percentage of hospital-acquired infections are caused by antibiotic-resistant S. aureus 25 . To assess a second system, we determined the impact of SPMs and vancomycin in S. aureus-initiated infections in murine dorsal skin pouches. SPM panel (RvD1, RvD5 and PD1; 100 ng each) and/or sub-optimal doses of vancomycin (2.5 mg) were administrated with S. aureus (10 5 c.f.u.) via intra-pouch injections. SPMs or vancomycin alone at 4 h each decreased exudate bacterial counts by approximately tenfold. Treatment with both further reduced bacterial counts by approximately 100-fold (Supplementary Fig. 11 a, b) . Similar results were obtained at 24 h; SPMs and vancomycin together gave significantly lower bacterial counts compared to those from each treatment alone (Fig. 4e ). In S. aureusinfected mice, histologic analysis demonstrated PMN infiltration and Gram stain positives within linings surrounding the pouch cavities ( Fig. 4f and Supplementary Fig. 11c ) that were markedly reduced by SPMs, vancomycin and their use together (Fig. 4f) .
A panel of cytokines/chemokines was also monitored. SPMs and vancomycin at 4 h significantly reduced S. aureus-induced IL-6 and GM-CSF in pouch exudates ( Supplementary Fig. 11 ), whereas neither alone was effective. It is noteworthy that vancomycin reduced LTB 4 and increased the Rv precursor 17-HDHA ( Supplementary Fig. 11 ). Other SPMs, including resolvin E1, protect mice from E. coli pneumonia and acute lung injury 26 and 15-epi-LXA 4 , an arachidonic acid-derived SPMs, enhances resolution of E. coli pulmonary inflammation 27 and macrophage phagocytosis 28 . Hence, it seems that specific SPM pathways are used by the host during Gram-positive and Gram-negative bacterial infections.
Here we carried out LM-metabolomics with infectious-inflammatory exudates and identified specific pro-resolving mediators that were also present in germ-free mice. RvD1 and RvD5 each accelerated resolution of E. coli infections and increased survival. SPMs given together with ciprofloxacin shortened resolution intervals, stimulated phagocyte containment of E. coli, enhanced bacterial killing, and protected mice from hypothermia. These are the first actions identified for RvD5. With human macrophages, both RvD1 and RvD5 stimulated phagocytosis of E. coli in a GPR32-dependent manner. SPMs also enhanced antibiotic effectiveness in clearing Gram-positive S. aureus skin infections. Together, these results indicate that stimulation of targeted host resolution responses by pro-resolving mediators in conjunction with bacterial-directed antibiotics lowers the required antibiotic doses for bacterial clearance. They illustrate new opportunities to address antibiotic resistance via lowering antibiotic use by also targeting host resolution programs. 
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